查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870669

犬用疫苗市場按疫苗類型、通路、最終用戶、技術和動物年齡層別分類－2025-2032年全球預測

Dog Vaccines Market by Vaccine Type, Distribution Channel, End User, Technology, Animal Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，犬類疫苗市場規模將達到 41.8 億美元，複合年成長率為 8.26%。

關鍵市場統計數據
基準年 2024 22.1億美元
預計年份：2025年 24億美元
預測年份 2032 41.8億美元
複合年成長率 (%) 8.26%

對現代犬用疫苗環境的簡要概述，將科學創新與商業性現實和營運影響聯繫起來。

科學技術的進步、寵物飼主期望的改變以及監管趨勢的演變，共同推動犬類醫療保健領域的持續發展。本執行摘要介紹犬用疫苗領域的研究，概述了影響相關利益者決策的關鍵促進因素、新興方法和商業性格局。其目標是為企業主管、臨床醫生和產品負責人提供指導，幫助他們了解影響疫苗研發、分銷和應用的結構性動態，並著重闡述其對營運和投資優先順序的實際意義。

技術進步的融合、獸醫護理模式的演變以及監管力度的加強如何推動犬用疫苗研發和供應的結構性變革

近年來，犬類疫苗的研發、評估和交付方式發生了許多轉折點，這不僅為價值鏈上的相關人員帶來了機遇，也帶來了挑戰。分子平台技術的進步開闢了新的治療途徑，而低溫運輸物流和數位健康技術的同步發展則革新了分銷模式，並為寵物飼主和獸醫專業人員之間的互動方式創造了新的空間。這些變化也反映了人們期望的更廣泛轉變。寵物飼主越來越像關注自身健康一樣關注寵物的健康，這推動了對更佳安全性和透明療效數據的需求。

評估2025年美國關稅對供應鏈韌性、採購決策和下游採購經濟性的策略影響

美國貿易政策的發展和關稅調整為採購計劃、跨境夥伴關係以及關鍵物資供應帶來了新的變數。關稅變化不僅影響成品疫苗的運輸，也影響上游原料、試劑和生產所需專用設備的流通。由於關稅波動會影響最終到岸成本，並促使企業將某些生產活動在地化，各組織正在重新審視籌資策略，並評估建立區域生產中心的可行性，以降低貿易波動帶來的風險。

整合疫苗類型、通路特徵、終端用戶偏好、技術平台和動物年齡層的可操作細分分析，以指導優先策略選擇。

了解細分市場的細微差別對於根據疫苗類型、通路、終端用戶需求、技術平台和動物年齡層來製定產品開發和上市策略至關重要。就疫苗類型而言，去活化疫苗、減毒活病毒疫苗和重組疫苗在開發和臨床特徵方面存在顯著差異，每種疫苗都具有獨特的安全性和儲存特性，這些特性會影響臨床應用和傳播策略。在分銷方面，通路分為機構管道和消費者管道，獸醫診所、線上零售商、藥房和動物診療機構各自以不同的方式影響著診療行為、庫存模式和客戶體驗。

一個綜合考慮美洲、歐洲、中東和非洲以及亞太地區監管差異、分銷管道能力和文化態度的全面區域觀點

區域趨勢在塑造犬用疫苗的監管時間表、分銷基礎設施和競爭格局方面發揮著至關重要的作用，每個主要區域都呈現出獨特的商業環境。在美洲，對伴侶動物醫療保健服務的高度重視，加上成熟的獸醫網路和私營部門對新型平台的大力投資，使得新配方在獲得監管核准和類似報銷機制後能夠迅速得到推廣應用。同時，歐洲、中東和非洲則形成了一個更多元化的生態系統，其監管協調程度、獸醫機構密度和購買力各不相同。所有這些都要求制定量身定做的上市和市場准入策略，充分考慮各區域的合規性和流通結構。

策略競爭分析表明，現有企業的優勢、生物技術創新和生產合作如何結合起來，在犬用疫苗領域創造差異化優勢。

犬用疫苗領域的競爭由成熟的獸用生技藥品公司、創新生物技術參與企業契約製造(CMO) 共同推動。儘管現有企業在分銷網路、獸醫信任度和監管經驗方面保持優勢，但新參與企業通常具有平台靈活性和差異化方法，能夠快速適應新的靶點，例如基於 mRNA 或載體的構建體。合作和授權是將商業性覆蓋範圍與技術創新相結合的常用方式。對於那些希望加快產品上市速度並避免在固定資產上進行過多資本投資的公司而言，與合約開發和生產組織 (CDMO) 建立策略聯盟也至關重要。

為經營團隊提供切實可行的、優先排序的策略建議，以協調創新、供應鏈韌性、相關人員參與和分銷執行，從而確保永續優勢。

動物健康領導企業應務實地結合創新投資、供應鏈強化和相關人員參與，以掌握機會並管控風險。首先，他們應優先考慮能夠滿足未滿足的臨床需求且具備可擴展生產能力的平台技術。這意味著評估DNA、mRNA和載體技術時，不僅要考慮其免疫學潛力，還要考慮其可生產性、低溫運輸影響和調節途徑。同時，他們應制定靈活的籌資策略，包括關鍵試劑的雙源供應，並考慮區域生產方案，以降低關稅和運輸中斷帶來的風險。

我們透過嚴格的混合方法調查方法來檢驗策略見解，該方法整合了關鍵相關利益者訪談、二手技術文獻和情境分析。

本研究採用混合方法，整合質性和量性數據，強調檢驗和跨學科檢驗。主要數據來源包括對獸醫、實驗室技術人員、採購負責人和行業高管的結構化訪談，以及針對相關利益者的研討會，旨在揭示該領域營運中的限制和應用促進因素。次要資料來源包括監管指導文件、同行評審文獻、臨床試驗報告和專利揭露，以確保技術準確性，並將技術趨勢置於科學規範的框架下進行分析。

綜合策略要務與實際考量，指導各組織在市場中穩健、實證地推廣犬用疫苗。

總之，犬用疫苗領域處於科學創新、不斷演進的分銷模式以及複雜的監管和貿易環境的交匯點。能夠成功駕馭這一領域的相關人員，是那些能夠將平台技術進步轉化為具有臨床意義的產品、調整分銷和教育以滿足終端用戶期望，並設計能夠抵禦政策和物流干擾的供應鏈的機構。其戰略要務是將技術雄心與營運務實相結合，以確保新的疫苗能夠安全可靠地惠及動物及其飼主，並建立長期的信任。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大基於mRNA的犬用疫苗的應用，以對抗新出現的感染疾病
  • 針對多種犬類病原體的新型多價疫苗監管核准進展
  • 家用自動注射器輸送系統在犬隻常規疫苗接種通訊協定中的需求不斷成長
  • 整合數位化疫苗接種追蹤平台，以最佳化犬隻疫苗接種合規性
  • 推廣聯合疫苗以減少就診次數並提高寵物飼主依從性
  • 根據犬隻基因風險分析結果制定個人化疫苗接種方案並進行推廣。
  • 透過生技公司與動物醫院連鎖機構的策略合作，加速疫苗研發。
  • 口服和經鼻吸入型疫苗製劑的快速成長，使得犬隻接種疫苗的過程更加輕鬆無壓力。
  • 重視通用感染疾病預防推動了頻譜犬用疫苗的投資。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章犬用疫苗疫苗類型分類）

  • 去活化疫苗
  • 減毒活病毒疫苗
  • 重組

第9章犬用疫苗市場（依通路分類）

  • 獸醫診所
  • 線上零售
  • 藥局
  • 獸醫診所

第10章犬用疫苗市場（依最終用戶分類）

  • 寵物主人
  • 研究所
  • 獸醫診所

第11章犬用疫苗市場（依技術分類）

  • DNA
  • mRNA
    • 非複製型
    • 自放大
  • 向量

第12章 依動物年齡層別分類的犬用疫苗市場

  • 成犬
  • 小狗
  • 老年犬

第13章 各地區犬用疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章犬用疫苗市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國犬用疫苗市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • Ceva Sante Animale SA
    • Virbac SA
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • HIPRA, SLU
    • Phibro Animal Health Corporation
Product Code: MRR-1A1A064C028B

The Dog Vaccines Market is projected to grow by USD 4.18 billion at a CAGR of 8.26% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.21 billion
Estimated Year [2025] USD 2.40 billion
Forecast Year [2032] USD 4.18 billion
CAGR (%) 8.26%

A concise orientation to the contemporary canine vaccine environment that maps scientific innovation to commercial realities and operational implications

The landscape of canine health management is undergoing sustained evolution as scientific advances, shifting pet owner expectations, and regulatory developments converge. This executive summary introduces a focused exploration of the dog vaccines domain, outlining critical drivers, emergent modalities, and the commercial contours that influence stakeholder decision-making. The objective is to orient executives, clinicians, and product strategists to the structural dynamics shaping vaccine development, distribution, and adoption while highlighting the practical implications for operations and investment prioritization.

Across veterinary practice and companion animal care, vaccination remains a cornerstone of preventive medicine. Nonetheless, recent years have seen a widening array of vaccine technologies, diversified delivery pathways, and more sophisticated demand signals from pet owners who increasingly value safety, convenience, and evidence of efficacy. This introduction frames subsequent sections by underscoring the interplay between scientific innovation and market-facing execution, setting expectations for how strategic choices will affect organizational competitiveness and animal welfare outcomes.

Moving forward, the assessment emphasizes translation of scientific capability into accessible products, the influence of channel economics on uptake, and the role of regulatory clarity in enabling novel modalities. In doing so, it prepares readers to interpret segmentation-level insights, regional variances, and the implications of trade policy on planning horizons and procurement strategies.

How converging technological advances, shifting veterinary care models, and regulatory tightening are driving a structural transformation across canine vaccine development and delivery

Recent years have seen several transformative shifts that are reshaping how vaccines for dogs are developed, vetted, and delivered, creating both opportunities and constraints for stakeholders across the value chain. Advances in molecular platforms have opened new therapeutic pathways, while parallel progress in cold-chain logistics and digital health has altered distribution models and created room for novel engagement with pet owners and veterinary professionals. These shifts also reflect broader changes in expectations: pet owners increasingly view companion animal health through a lens of human-grade care, driving demand for higher safety profiles and more transparent efficacy data.

At the same time, regulatory agencies have become more proactive in articulating requirements for newer modalities, leading to clearer pathways for DNA, mRNA, and vector-based candidates but also imposing stringent demonstration of long-term safety. The proliferation of online retail and telehealth-enabled veterinary services has disrupted traditional distribution norms and forced incumbents to adapt service models and client communications. Furthermore, integration of genomic surveillance and pathogen mapping into routine practice is enabling more targeted vaccine design, shortening the loop between outbreak detection and product iteration.

Consequently, innovators and established manufacturers must balance accelerated R&D trajectories with rigorous evidence generation and supply chain resilience. As a result, strategic imperatives now include investment in platform interoperability, enhanced stakeholder education, and adaptive manufacturing capacity that can respond to both routine immunization schedules and emerging pathogen threats.

Assessing the strategic consequences of United States tariff measures in 2025 on supply chain resilience, sourcing decisions, and downstream procurement economics

Trade policy developments and tariff adjustments enacted by the United States have introduced new variables into planning for procurement, cross-border partnerships, and the supply of critical inputs. Tariff changes affect not only finished vaccine shipments but also the upstream flow of raw materials, reagents, and specialized equipment that are essential to production. As tariffs alter landed costs and create incentives to localize specific manufacturing activities, organizations are reassessing sourcing strategies and evaluating the feasibility of regional production hubs to mitigate exposure to trade volatility.

These shifts have also prompted companies to reexamine contractual frameworks with suppliers and distributors, placing greater emphasis on flexibility clauses and dual-sourcing arrangements. In parallel, licensors and contract manufacturers are exploring alternative commercial models that can cushion the impact of tariff-induced cost fluctuations, including long-term supply agreements and onshore capacity investments. For stakeholders engaged in clinical development, changes in import duties affecting laboratory reagents and animal health diagnostics are being monitored closely, since procurement timelines may be lengthened when sourcing corridors become less predictable.

Ultimately, the cumulative impact of tariff measures in 2025 is encouraging a strategic pivot toward resilient supply chain design, stronger supplier relationships, and greater transparency into total landed costs. Executives should consider tariff exposure as one component of a broader risk management framework that includes regulatory, operational, and reputational factors.

Actionable segmentation intelligence that aligns vaccine type, channel dynamics, end-user preferences, technological platforms, and animal age cohorts to inform prioritized strategic choices

A nuanced understanding of segmentation is essential for tailoring product development and go-to-market strategies across vaccine modality, distribution pathways, end-user needs, technological platforms, and animal age cohorts. When considering vaccine type, there is a clear differentiation in development and clinical profiling between inactivated preparations, live attenuated formulations, and recombinant constructs, each presenting unique safety and storage characteristics that influence clinical adoption and communication strategies. Transitioning to distribution considerations, channels span institutional settings and consumer-facing outlets, with Animal Hospitals, Online Retail, Pharmacies, and Veterinary Clinics each shaping point-of-care dynamics, stocking patterns, and customer experience in distinct ways.

End-user segmentation reveals divergent decision criteria: Pet Owners prioritize convenience, perceived safety, and value communication; Research Institutes focus on assay compatibility and reproducibility for experimental work; Veterinary Hospitals require proven efficacy, ease of administration, and reliable supply. Technological segmentation is particularly consequential as DNA, mRNA, and Vector platforms demonstrate different timelines for regulatory validation, manufacturing scaling, and cold-chain dependencies; within mRNA there is further technical distinction between Non-Replicating and Self-Amplifying formats, which carries implications for dosing, immunogenicity, and production throughput. Age-based segmentation underscores clinical differentiation across Adult, Puppy, and Senior cohorts, given that immune competency, dosing schedules, and comorbidity profiles vary with age and thereby impact safety monitoring and communication strategies.

Integrated segmentation analysis indicates that winning strategies will align product profiles with channel economics and end-user expectations while leveraging platform advantages selectively for age cohorts that realize the greatest clinical benefit. Accordingly, cross-functional planning teams should map segmentation intersections to prioritize clinical programs, distribution investments, and educational outreach that resonate with each stakeholder cluster.

Comprehensive regional vantage points that reconcile regulatory diversity, channel capacity, and cultural attitudes across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics play a fundamental role in shaping regulatory timelines, distribution infrastructure, and the competitive landscape for canine vaccines, with distinct operating contexts across major geographies. In the Americas, a strong emphasis on companion animal health services is paired with well-established veterinary networks and robust private-sector investment in novel platforms, which fosters rapid uptake of new formulations when regulatory clearance and reimbursement-like mechanisms align. Conversely, Europe, Middle East & Africa presents a more heterogeneous ecosystem characterized by variable regulatory harmonization, differences in veterinary practice density, and diverse purchasing power, all of which necessitate tailored launch and access strategies that account for localized compliance and channel structures.

Asia-Pacific exhibits a mix of high-volume markets with rapidly modernizing veterinary infrastructure and emerging regions where access constraints and differing clinical priorities shape demand. Across all regions, cold-chain logistics, import regulations, and local manufacturing capacity influence placement decisions and partnership models. Moreover, cultural attitudes toward pet ownership, preventive care awareness, and the role of veterinarians in guiding vaccination choices introduce behavioral nuances that companies must address through locally adapted education and outreach programs.

Taken together, regional planning should emphasize regulatory due diligence, partnership selection that leverages local channel strengths, and investment in distribution capabilities that reflect the operational realities of each geography. This regional sensitivity will enable more effective product rollouts and greater alignment with clinician and pet owner expectations.

Strategic competitive landscape analysis showing how incumbent strengths, biotech innovation, and manufacturing partnerships converge to create differentiated advantage in the canine vaccine sector

Competitive dynamics in the dog vaccine sector are being influenced by a mix of established veterinary biologics firms, innovative biotechnology entrants, and contract manufacturers that support specialized platform scale-up. Incumbents retain advantages in distribution networks, practitioner trust, and regulatory experience, while newer entrants often bring platform agility and differentiated approaches such as mRNA or vector-based constructs that can be adapted rapidly to emerging targets. Partnerships and licensing deals are common mechanisms to combine commercial reach with technical novelty, and strategic alliances with contract development and manufacturing organizations are critical for firms seeking to accelerate time-to-market without overextending capital investment in fixed assets.

In addition, increasing emphasis on data-driven safety monitoring and post-marketing evidence collection is favoring competitors that can integrate digital tools and real-world data capture into their product propositions. Companies that invest in robust pharmacovigilance frameworks and clinician education programs are more likely to build long-term trust with veterinary professionals and pet owners. Meanwhile, supply chain reliability and the ability to manage cold-chain-sensitive products at scale remain differentiators that affect commercial sustainability. Consequently, market leaders will be those that combine technological innovation with operational excellence and a disciplined approach to regulatory engagement and stakeholder communication.

Practical and prioritized strategic recommendations for executives to align innovation, supply chain resilience, stakeholder engagement, and distribution execution for sustained advantage

Leaders in the animal health arena should pursue a pragmatic blend of innovation investment, supply chain fortification, and stakeholder engagement to capture opportunity while managing risk. First, prioritize platform technologies that align with clinical unmet needs and can be supported by scalable manufacturing; this means evaluating DNA, mRNA, and vector approaches not only for their immunological potential but for manufacturability, cold-chain implications, and regulatory pathways. Concurrently, develop flexible sourcing strategies that include dual suppliers for critical reagents and consider regional production options to reduce exposure to tariff and shipping disruptions.

Second, invest in clinician and owner education to foster confidence in newer modalities and to clarify administration schedules across life stages from puppy through senior animals. Third, enhance pharmacovigilance and real-world evidence programs to accelerate acceptance and to inform iterative product improvement. Fourth, design distribution strategies that reflect channel-specific behaviors, ensuring that Animal Hospitals, Online Retail, Pharmacies, and Veterinary Clinics each receive tailored product presentation, training, and logistical support. Finally, cultivate strategic partnerships with research institutions and contract manufacturers to balance in-house capability with external expertise and capacity, enabling rapid responses to pathogen emergence while maintaining operational discipline.

A rigorous mixed-methods research approach that integrates primary stakeholder interviews, secondary technical literature, and scenario analysis to validate strategic insights

This research synthesizes qualitative and quantitative inputs through a mixed-methods approach that emphasizes triangulation and subject-matter validation. Primary inputs include structured interviews with veterinary clinicians, laboratory scientists, procurement professionals, and industry executives, complemented by targeted stakeholder workshops that surfaced on-the-ground operational constraints and adoption drivers. Secondary sources encompass regulatory guidance documents, peer-reviewed literature, clinical trial reports, and patent disclosures to ensure technical accuracy and to situate technological trends within the scientific canon.

Analytical methods included cross-segmentation mapping to identify high-impact intersections among vaccine type, distribution channels, end-user priorities, technology platform, and animal age group. Scenario analysis was applied to evaluate supply chain and trade-policy sensitivities, while expert review panels validated assumptions and interpretation of complex technical issues. Throughout the process, care was taken to corroborate claims with multiple evidence streams and to document uncertainty explicitly, enabling readers to distinguish between well-supported insight and areas requiring further empirical work. This methodological rigor underpins the recommendations and ensures that strategic choices are grounded in a defensible evidentiary base.

A synthesis of strategic imperatives and practical considerations that guide organizations toward resilient, evidence-driven deployment of canine vaccines across markets

In closing, the dog vaccines domain sits at the intersection of scientific innovation, evolving distribution models, and complex regulatory and trade environments. Stakeholders who successfully navigate this space will be those that translate platform advances into clinically meaningful products, adapt distribution and education to meet end-user expectations, and design supply chains that withstand policy and logistical disruption. The strategic imperative is to couple technological ambition with operational pragmatism so that new modalities can reach animals and owners safely, reliably, and in a way that supports long-term trust.

Looking ahead, the organizations that win will be those that build adaptive capability across R&D, manufacturing, and commercial operations, while maintaining a relentless focus on evidence generation and stakeholder communication. By aligning segmentation-specific product design with regional realities and robust risk management, leaders can achieve durable impact in improving canine health outcomes and in creating sustainable commercial pathways for next-generation vaccines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of mRNA-based canine vaccines to combat emerging infectious diseases
  • 5.2. Regulatory approval progress for novel multivalent vaccines targeting multiple canine pathogens
  • 5.3. Rising demand for at-home auto-injector delivery systems in routine dog vaccination protocols
  • 5.4. Integration of digital immunization tracking platforms to optimize canine vaccination compliance
  • 5.5. Expansion of combination vaccines reducing veterinary visits and improving owner adherence
  • 5.6. Growth of personalized vaccination schedules based on canine genetic risk profiling
  • 5.7. Strategic partnerships between biotech innovators and veterinary chains to accelerate vaccine R&D
  • 5.8. Surge in oral and intranasal vaccine formulations for stress-free canine administration
  • 5.9. Focus on zoonotic disease prevention driving investment in broad-spectrum dog vaccines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dog Vaccines Market, by Vaccine Type

  • 8.1. Inactivated
  • 8.2. Live Attenuated
  • 8.3. Recombinant

9. Dog Vaccines Market, by Distribution Channel

  • 9.1. Animal Hospitals
  • 9.2. Online Retail
  • 9.3. Pharmacies
  • 9.4. Veterinary Clinics

10. Dog Vaccines Market, by End User

  • 10.1. Pet Owners
  • 10.2. Research Institutes
  • 10.3. Veterinary Hospitals

11. Dog Vaccines Market, by Technology

  • 11.1. DNA
  • 11.2. mRNA
    • 11.2.1. Non-Replicating
    • 11.2.2. Self-Amplifying
  • 11.3. Vector

12. Dog Vaccines Market, by Animal Age Group

  • 12.1. Adult
  • 12.2. Puppy
  • 12.3. Senior

13. Dog Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dog Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dog Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Zoetis Inc.
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. Boehringer Ingelheim International GmbH
    • 16.3.4. Elanco Animal Health Incorporated
    • 16.3.5. Ceva Sante Animale S.A.
    • 16.3.6. Virbac S.A.
    • 16.3.7. Vetoquinol S.A.
    • 16.3.8. Dechra Pharmaceuticals PLC
    • 16.3.9. HIPRA, S.L.U.
    • 16.3.10. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DOG VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DOG VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DOG VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DOG VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DOG VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DOG VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS DOG VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS DOG VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GCC DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. GCC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. GCC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. GCC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. GCC DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. GCC DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GCC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. GCC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. GCC DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 266. GCC DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 267. GCC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GCC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. G7 DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. G7 DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. G7 DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. G7 DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. G7 DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. G7 DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. G7 DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. G7 DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. G7 DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 308. G7 DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 309. G7 DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. G7 DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. NATO DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. NATO DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. NATO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. NATO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. NATO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. NATO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. NATO DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. NATO DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. NATO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. NATO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. NATO DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 322. NATO DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 323. NATO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. NATO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED STATES DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 339. CANADA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. CANADA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. CANADA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 342. CANADA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 343. CANADA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. CANADA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. CANADA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 346. CANADA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 347. CANADA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 348. CANADA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 349. CANADA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 350. CANADA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 351. MEXICO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. MEXICO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 353. MEXICO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 354. MEXICO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 355. MEXICO DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 356. MEXICO DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 357. MEXICO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 358. MEXICO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 359. MEXICO DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 360. MEXICO DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 361. MEXICO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 362. MEXICO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 363. BRAZIL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 364. BRAZIL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 365. BRAZIL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 366. BRAZIL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 367. BRAZIL DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 368. BRAZIL DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 369. BRAZIL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)

TA